

Analyst

John Hester 612 8224 2871

Authorisation

David Coates 612 8224 2887

Oncosil Medical (OSL)

Now Screening For Patients

Speculative

See key risks on Page 4 and Biotechnology Risk Warning on Page 6. Speculative securities may not be suitable for Retail Clients.

Recommendation

Buy (unchanged)

Price

\$0.115

Valuation

\$0.42 (unchanged)

Risk

Speculative

GICS Sector

Pharmaceuticals & Biotechnology

Expected Return

Capital growth	265%
Dividend yield	0.0%
Total expected return	265%


Company Data & Ratios

Enterprise value	\$74.3m
Market cap	\$95.3m
Issued capital	828.6m
Free float	100%
Avg. daily val. (52wk)	\$400,000
12 month price range	\$0.05 - \$0.21

Price Performance

	(1m)	(3m)	(12m)
Price (A\$)	0.12	0.11	0.06
Absolute (%)	-4.17	9.52	86.17
Rel market (%)	-3.56	6.22	94.32

Absolute Price



SOURCE: IRESS

Revenues Now Imminent

The company hosted an investor update today, the key points from which are as follows. 1) Leading hospitals in the UK are now screening for patients. By implication the funding issue has been resolved – at least in the short term. The company didn't elaborate on pricing or whether these were public or private patient being screened, nevertheless the key point is that first commercial revenues are now imminent. 2) Hospitals in the UK are now increasingly open for business as COVID restrictions ease. Restrictions on OSL team members accessing these hospital campuses has also eased, hence surgeon training can recommence 3) We expect a further update on survival for patients from the Panco study (being the approval study for Europe and the UK) later this calendar year. While the median survival is unlikely to move significantly, most of the 9 patients who underwent surgery following down staging of tumours remain alive today. 24% of patients in the study became eligible for surgery who otherwise would have had a life expectancy of only 8.5 months from diagnosis. A three year survival benefit for these patients is not unreasonable 4) OSL awaits the outcome of its Humanitarian Device Exemption (HDE) application to the FDA for the treatment of bile duct cancer. The period for the review process is 75 days, hence the outcome should be known in mid October. If successful the Oncosil therapy may be used immediately for the treatment of the disease in the US. The pathway for the use of Oncosil in the treatment of pancreatic cancer in the US remains unclear. A large randomised study will be required, all options remains open on the funding. If the HDE is granted, we believe off label use in locally advanced pancreatic cancer is likely.

Investment View – Retain Buy (Speculative)

The company is well capitalised with cash of \$21m. There are several important catalysts for the stock in the coming weeks and months as outlined above. In addition the delays to commercialisation from COVID are now easing, hence we are virtually certain of commercial revenues this year. No changes to earnings. Price target unchanged at 42c. Retain speculative (Buy) recommendation.

Earnings Forecast

June Year End	FY20	FY21e	FY22e	FY23e
Revenues	2.8	7.2	15.5	20.9
EBITDA \$m	-4.4	-3.4	-7.6	-4.3
NPAT (underlying) \$m	-4.3	-3.3	-7.5	-3.8
NPAT (reported) \$m	-4.3	-3.3	-7.5	-3.8
EPS underlying (cps)	-0.7	-0.4	-0.9	-0.5
EPS growth %	-52%	-40%	128%	-48%
PER (x)	nm	nm	nm	nm
FCF yield (%)	nm	nm	nm	nm
EV/EBITDA (x)	nm	nm	nm	nm
Dividend (cps)	-	-	-	-
Franking	0%	0%	0%	0%
Yield %	0.0%	0.0%	0.0%	0.0%
ROE %	-20.0%	-18.1%	-67.5%	-59.0%

SOURCE: BELL POTTER SECURITIES ESTIMATES

Revenues Imminent

ADDRESSABLE MARKET

We have now revised our estimate of total addressable market as follows:

Figure 1 – Total Addressable Market (TAM) Estimate

	Locally Advanced Pancreatic Cancer				TAM	Bile Duct	All Markets
	United Kingdom	European Union	USA	Australia		USA	TAM
Estimated Annual Incidence	8,700	79,000	48,000	4,300		8,000	
LAPC @ 40%	3,480	31,600	19,200	1,720			
Borderline resection	870	7,900	4,800	430			
Revenue per patient (local currency)	8,000	12,000	25,000	20,000		25,000	
FX Rate	0.54975	0.617575	0.7349	1.00		0.7349	
A\$m	63	768	816	43	1,690	34	1,724

SOURCE: BELL POTTER SECURITIES ESTIMATES

In the UK, negotiations are underway for the treatment of patients in the NHS as well as via private hospitals. The private hospitals will support self pay and probably some reimbursement by private health insurance. Approximately 24% of London residents have PHI, hence this is a lucrative market.

Within the NHS, there are just 26 hospitals across the entire UK with the surgical facilities to perform the procedure. Specialist funding is likely available for a limited number of procedures each year.

In the US, assuming the Humanitarian Device Exemption (HDE) is successful the inclusion of this market adds an estimated \$34m to the total addressable market. We are yet to include any sales for the bile duct market (cholangiocarcinoma) in the forecast as there is no launch plan at the moment and not a great deal of data with which to market the product. We expect initial uptake will be slow.

The absence of a PMA for locally advanced pancreatic cancer (LAPC) in the US will not prevent early adopters from initiating investigator led clinical studies in pancreatic cancer, in fact, we believe this is likely once the HDE is approved. Ethics approval is likely given the data from Panco and the fact that the product is used in conjunction with the standard of care chemotherapy. If this is the case, the use of oncosil therapy for pancreatic cancer would be off label, however, given the survival benefit demonstrated in the Panco trial, US patients are likely to demand the treatment.

Reimbursement is another matter. If off label use in LAPC does proceed, self pay is likely in the first instance.

Many therapies are used off label in the US (including most of CSL's IGG products) for a variety of related conditions. The only catch is that the company cannot market the product off label, however, it can certainly present factual data at conferences (such as the survival data from the Panco study). OSL has been awarded breakthrough designation for the treatment of pancreatic cancer in the US.

The company is yet to discuss its regulatory pathway for LAPC in the US in any great detail. It has an IDE for pancreatic cancer. At least one clinical trial will be required (and probably only one), the nature and size of the trial are yet to be revealed.

We believe it is unlikely that OSL will gain a US approval on the basis of a post hoc literature review (as was the case for the CE Mark).

Investigator led studies in LAPC are likely in the US ahead of an approval study

VALUATION

There are no changes to earnings. We retain our valuation of \$0.42

Cash at 30 June 2020 was \$21m. Based on our forecast the company has sufficient cash for a least two years, however, the forecasts is highly subjective with the key variables being the uptake rate for sales, marketing spend and R&D spend.

The forecast includes A\$36m for a future US clinical study, however the nature of this remains uncertain, hence we retain our Buy (speculative) rating. Once the company begins to generate revenues in Europe some further funding options may arise including the sale of rights to Japan and China.

Oncosil Limited

Oncosil Limited is a single product medical device company. Oncosil is a first in class intratumoral brachytherapy device seeking approval for the treatment of inoperable pancreatic cancer.

The initial target market for OncoSil™ is in pancreatic cancer where there remains a high unmet clinical need. It is estimated that each year there are more than new 87,000 cases in Europe and 48,000 new cases in the US. Five year survival is less than 1 in 20. The company also has aspirations to develop Oncosil for Primary Liver Cancer.

The company completed the PanCo study in 2019 and received the CE Mark to treat inoperable locally advanced pancreatic cancer in April 2020. The US FDA granted an Investigational Device Exemption (IDE) in August 2016 and awarded Breakthrough designation in March 2020. The trial design for a US approval study is yet to be discussed with the FDA. The company will be required to conduct at least 1 large pivotal study in the US in order to gain approval.

KEY RISKS

Emerging therapy – Medical science continues to evolve and new therapies are constantly emerging. The oncology field attracts more R&D investment than most and consequently there are many new drugs in the pipeline. Despite this, based on our enquiries there are no late stage drugs in development for the treatment of Pancreatic Cancer. Clinical trials frequently produce good result at the phase II stage of development, however, these often fail to repeat in broader populations across multiple treatment centres. While the threat of an emerging therapy is constant, it is not imminent.

Medical Community is slow to adopt new therapy – Especially where the treatment is not supported by evidence from a large randomised controlled study. Consequently, our assumptions relating to adoption rates may overestimate potential revenues. Oncosil faces the additional challenge that it is the first brachytherapy for the treatment of pancreatic cancer.

Funding – Oncosil is likely to require further equity in order to complete the clinical program.

Clinical Risk – OSL has an investigational device exemption in the US for pancreatic cancer. Success in the clinic is required in order for the product to be marketed in the US. There is no guarantee that results from previous studies will be repeated in a broader, multi centre trial.

Other commercial risks - The validity of patents which protect the future income stream from OncoSil are yet to be tested. In addition, normal commercial risk relating to reliance on suppliers also apply. Oncosil Medical Ltd does not manufacture the Oncosil product and is entirely dependent on a small number of hi-tech manufacturers for supply to its customer base. OncoSil is a highly toxic material. Its manufacture, storage, transport and use are each subject to regulatory requirements. OncoSil relies on various external parties to manage these risks in the normal course of their business.

Table 1 - Financial summary

Profit & Loss (A\$m)	FY19	FY20	FY21e	FY22e	FY23e
Year Ending June					
Dose sales (units)	-	-	175	490	1,300
Net revenue from product sales	-	-	4.2	10.5	17.9
COGS	-	-	0.8	-2.1	-3.6
Gross profit	-	-	3.4	8.4	14.3
GP margin			80%	80%	80%
R&D incentive/Upfront receipts	3.6	2.8	3.0	5.0	3.0
Total revenues	3.6	2.8	7.2	15.5	20.9
Clinical trials	-5.6	-3.7	-2.0	-12.0	-12.0
Other expenses	-6.7	-3.5	-7.8	-9.0	-9.6
EBITDA	-8.7	-4.4	-3.4	-7.6	-4.3
Depreciation	0.0	0.0	0.0	0.0	0.0
Amortisation	0.0	0.0	0.0	0.0	0.0
EBIT	-8.7	-4.4	-3.4	-7.6	-4.3
Sundry income	0.2	0.1	0.1	0.1	0.5
Pre tax profit	-8.5	-4.3	-3.3	-7.5	-3.8
Tax expense	-	-	-	-	-
NPAT- normalised	-8.5	-4.3	-3.3	-7.5	-3.8
Net abnormal items	-	-	-	-	-
Reported NPAT	-8.5	-4.3	-3.3	-7.5	-3.8
Cashflow (A\$m)	FY19	FY20	FY21e	FY22e	FY23e
Gross cashflow	-7.7	-4.7	-0.9	-8.1	-5.9
Net interest	0.2	0.1	0.1	0.1	0.5
Other	0.0	0.1	0.0	0.0	0.0
Operating cash flow	-7.5	-4.5	-0.8	-8.0	-5.4
Maintenance capex	0.0	0.0	0.0	0.0	0.0
Capitalised clinical trial spend	0.0	0.0	0.0	0.0	0.0
Free cash flow	-7.5	-4.5	-0.8	-8.1	-5.4
Business acquisitions	0.0	0.0	0.0	0.0	0.0
Proceeds from issuance	0.0	17.9	0.0	0.0	0.0
Movement in borrowings	0.0	-0.1	0.0	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0
Change in cash held	(7.5)	13.3	(0.8)	(8.1)	(5.4)
Cash at beginning of period	15.2	7.7	21.0	20.2	12.1
Cash at year end	7.7	21.0	20.2	12.1	6.7
Balance Sheet (A\$m)	FY19	FY20	FY21e	FY22e	FY23e
Cash	7.7	21.0	20.2	12.1	6.7
Receivables	3.8	2.8	0.3	0.9	2.4
Short term investments	-	-	-	-	-
Other current assets	0.1	0.1	0.1	0.1	0.1
Property, Plant and Equipment	0.1	0.1	0.1	0.2	0.2
Total assets	11.7	24.0	20.7	13.3	9.4
Trade payables	0.8	1.8	1.8	1.8	1.8
Other provisions	0.2	0.3	0.3	0.3	0.3
Total Liabilities	1.0	2.1	2.1	2.1	2.1
Net Assets	10.7	21.9	18.6	11.2	7.3
Share capital	52.3	70.1	70.1	70.1	70.1
Retained earnings	(47.6)	(51.9)	(55.2)	(62.6)	(66.4)
Reserves	6.0	3.7	3.7	3.7	3.7
Shareholders Equity	10.7	21.9	18.6	11.2	7.4

Valuation Ratios (A\$m)	FY19	FY20	FY21e	FY22e	FY23e
Reported EPS (cps)	-1.4	-0.7	-0.4	-0.9	-0.5
Normalised EPS (cps)	-1.4	-0.7	-0.4	-0.9	-0.5
EPS growth (%)	nm	-52%	-40%	128%	-0.5
PE(x)	nm	nm	nm	nm	nm
EV/EBITDA (x)	nm	nm	nm	nm	nm
EV/EBIT (x)	nm	nm	nm	nm	nm
NTA (cps)	1.7	2.6	2.3	1.4	0.9
P/NTA (x)	0.1	0.0	0.1	0.1	0.1
Book Value (cps)	1.7	2.6	2.3	1.4	0.9
Price/Book (x)	0.1	0.0	0.1	0.1	0.1
DPS (cps)	-	-	-	-	-
Payout ratio %	0%	0%	0%	0%	0%
Dividend Yield %	0.0%	0.0%	0.0%	0.0%	0.0%
Franking %	160%	0%	0%	0%	0%
FCF yield %	-1051%	-483%	-84%	-849%	-567%
Net debt/Equity	0%	0%	0%	0%	0%
Net debt/Assets	0%	0%	0%	0%	0%
Gearing	net cash	net cash	net cash	net cash	net cash
Net debt/EBITDA (x)	n/a	n/a	n/a	n/a	n/a
Interest cover (x)	n/a	n/a	n/a	n/a	n/a

Dose sales (Units)	FY21e	FY22e	FY23e
Europe	175	400	1,000
USA	-	-	-
Australia/Asia Pacific	-	90	300
Total dose sales	175	490	1,300

SOURCE: BELL POTTER SECURITIES ESTIMATES

Recommendation structure

Buy: Expect >15% total return on a 12 month view. For stocks regarded as 'Speculative' a return of >30% is expected.

Hold: Expect total return between -5% and 15% on a 12 month view

Sell: Expect <-5% total return on a 12 month view

Speculative Investments are either start-up enterprises with nil or only prospective operations or recently commenced operations with only forecast cash flows, or companies that have commenced operations or have been in operation for some time but have only forecast cash flows and/or a stressed balance sheet.

Such investments may carry an exceptionally high level of capital risk and volatility of returns.

Research Team

Staff Member	Title/Sector	Phone	@bellpotter.com.au
TS Lim	Head of Research/Banks	612 8224 2810	tslim
Analysts			
Lafitani Sotiriou	Diversified Financials/Fintech	613 9235 1668	Isotiriou
John Hester	Healthcare	612 8224 2871	jhester
Tanushree Jain	Healthcare	612 8224 2849	tnjain
Elyse Shapiro	Healthcare	613 9235 1877	eshapiro
Steven Anastasiou	Industrials	613 9235 1952	sanastasiou
James Filius	Industrials	613 9235 1612	jfilius
Sam Haddad	Industrials	612 8224 2819	shaddad
Alex McLean	Industrials	612 8224 2886	amclean
Hamish Murray	Industrials	613 9235 1813	hmurray
Chris Savage	Industrials	612 8224 2835	csavage
Jonathan Snape	Industrials	613 9235 1601	jsnape
Damien Williamson	Industrials	613 9235 1958	dwilliamson
Peter Arden	Resources	613 9235 1833	parden
David Coates	Resources	612 8224 2887	dcoates
Stuart Howe	Resources	613 9235 1856	showe
Associate			
Joseph House	Associate Analyst	+61 3 9235 1624	jhouse

Bell Potter Securities Limited

ACN 25 006 390 7721
Level 29, 101 Collins Street
Melbourne, Victoria, 3000
Telephone +61 3 9256 8700
www.bellpotter.com.au

Bell Potter Securities (HK) Limited

Room 1701, 17/F
Posperity Tower, 39 Queens Road
Central, Hong Kong, 0000
Telephone +852 3750 8400

Bell Potter Securities (US) LLC

Floor 39
444 Madison Avenue, New York
NY 10022, U.S.A
Telephone +1 917 819 1410

Bell Potter Securities (UK) Limited

16 Berkeley Street
London, England
W1J 8DZ, United Kingdom
Telephone +44 7734 2929

The following may affect your legal rights. Important Disclaimer:

This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the two specified countries. **In Hong Kong**, this research is being distributed by Bell Potter Securities (HK) Limited which is licensed and regulated by the Securities and Futures Commission, Hong Kong. **In the United States**, this research is issued and distributed by Bell Potter Securities (US) LLC which is a registered broker-dealer and member of FINRA. Any person receiving this report from Bell Potter Securities (US) LLC and wishing to transact in any security described herein should do so with Bell Potter Securities (US) LLC. This is general investment advice only and does not constitute personal advice to any person. Because this document has been prepared without consideration of any specific client's financial situation, particular needs and investment objectives ('relevant personal circumstances'), a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the representative of such licensee, who has provided you with this report by arrangement with Bell Potter Securities Limited) should be made aware of your relevant personal circumstances and consulted before any investment decision is made on the basis of this document. While this document is based on information from sources which are considered reliable, Bell Potter Securities Limited has not verified independently the information contained in the document and Bell Potter Securities Limited and its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility for updating any advice, views opinions, or recommendations contained in this document or for correcting any error or omission which may become apparent after the document has been issued. Except insofar as liability under any statute cannot be excluded. Bell Potter Securities Limited and its directors, employees and consultants do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this document or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this document or any other person.

Research Policies: For Bell Potter's Research Coverage Decision Making Process and Research Independence Policy, please refer to our company website:

<https://bellpotter.com.au/research-independence-policy/>

Disclosure of interest: Bell Potter Securities Limited, its employees, consultants and its associates within the meaning of Chapter 7 of the Corporations Law may receive commissions, underwriting and management fees from transactions involving securities referred to in this document (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this document.

Disclosure: Bell Potter Securities acted as Lead manager of the company's \$19m placement and rights issue in May 2020 and received fees for that service.

Biotechnology Risk Warning:

The fact that the intellectual property base of a typical biotechnology company lies in science not generally regarded as accessible to the layman adds further to the riskiness with which biotechnology investments ought to be regarded. Clinical and regulatory risks are inherent in biotechnology stocks. Biotechnology developers usually seek US FDA approval for their technology which is a long and arduous three phase process to prove the safety, effectiveness and appropriate application or use of the developed drug and even after approval a drug can be the subject of an FDA investigation of subsequently discovered possible links between the drug and other diseases not previously diagnosed. Furthermore, the Australian exchange listed biotechnology sector is subject to influence by the global biotechnology sector, particularly that in the USA. Consequently, Australian exchange listed biotechnology stocks can experience sharp movements, both upwards and downwards, in both valuations and share prices, as a result of a re-rating of the sector both globally and in the USA, in particular. Investors are advised to be cognisant of these risks before buying such a stock.

ANALYST CERTIFICATION: Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.